PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Offering a more affordable fitness class solution through training small groups and providing unparalleled client care with 1-on-1 personal training sessions. Outrivals has grown rapidly since launching 3 years ago near the famous Old Street Roundabout and are raising funds to open 2 new sites, with plans to have a portfolio of 15 branches over the next 5 years. The company has a high retention rate, with a client life cycle averaging one year.
days to go:
Expired
investment:
£88,450
DMALINK, an electronic trading platform, fosters a transparent currency market for institutional FX and cryptocurrency traders, achieving over $8 billion monthly transactions since its Q4 '22 techstack launch, collaborating with major institutions and holding proprietary intellectual property.
days to go:
Expired
investment:
£480,856
Nebeus aims to bridge the gap between cryptocurrency and cash, providing people with instant crypto-backed cash services for everyday use. The company argues that there is an equivalent of $400 billion held in more than 55 million crypto wallets around the world which cannot be used further than keeping as an investment. It aims to change this scenario. Nebeus's core product is its 'Instant Loans' offering. It also offers users to do mobile top-ups, conduct Card2Card transfers, and send cash to Points of Sale (PoS) amongst other financial services. The company is working to come out with a 'Nebeus Mastercard' in partnership with Railsbank in Q1 of 2021. Nebeus has more than 60,000 users on its portal and has overseen transactions over £30 million to date. The company has featured in publications like The Independent, Forbes, and Bloomberg to name a few. It will use the investment for growth and marketing, the rollout of Nebeus Mastercard rollout, for growing its team, and for Research and Development (R&D).
days to go:
Expired
investment:
£862,580
AxiaFunder is a commercial litigation funding platform that offers investors access to pre-vetted cases. The platform aims to connect eligible investors like sophisticated retail investors, high-net-worth, and typically institutions with claimants seeking funding. Launched in January 2019 with the first case fully funded within seven days and the third in 7 hours; 5 cases financed to date, attracted over 355 registered investors so far including several institutions and has featured in several prominent publications including the Financial Times, Times and City AM. Also, they have won the 'Best Commercial Litigation Crowdfunding Platform 2019' award by Wealth & Finance. AxiaFunder plans to use the proceeds to make key hires particularly to strengthen its case origination, further development of its platform and marketing to build the AxiaFunder brand and grow its investor base.
days to go:
Expired
investment:
£256,780
Brother Cycles' bikes are designed in the UK and handcrafted from steel to be ridden all around the world. Their products are sold at independent retailers throughout the UK and Europe, in addition to their own website. Since 2015, Brother Cycles has seen an increase of 119% in turnover and is trading at a net profit with 2018 currently being their strongest sales period.
In the summer of 2018, the company launched their B2B website and within the first week, more than 40 stockists had signed up to trade with the business. Brother in the Wild is Brother Cycle's annual cycling festival, which saw 180 cyclists joining in 2018 and predicted to grow exponentially in the coming years.
Current revenue stream include their wide product range with continually improving profit margins, B2B sales and B2C sales through customers purchasing goods directly from Brother Cycle's website. Funds are being raised to launch two new products in 2019, which consist of a technical adventure bike and a high-end road bike.
days to go:
Expired
investment:
£105,497
